Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures
A recombinant subunit vaccine (Shingrix<sup>®</sup>) was recently licensed for use against herpes zoster. This vaccine is based on glycoprotein E (gE) of varicella zoster virus (VZV), the most abundantly expressed protein of VZV, harboring sites for N- and O-linked glycosylation...
Main Authors: | Rickard Nordén, Jonas Nilsson, Ebba Samuelsson, Christian Risinger, Carina Sihlbom, Ola Blixt, Göran Larson, Sigvard Olofsson, Tomas Bergström |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/4/954 |
Similar Items
-
An adult co-presented with varicella and herpes zoster caused by varicella zoster virus genotype J, China: a case report
by: Guangcheng Xie, et al.
Published: (2020-06-01) -
Varicella-zoster virus infections – antiviral therapy and diagnosis
by: Sauerbrei, Andreas
Published: (2016-02-01) -
Varicella-zoster virus encephalitis in an AIDS patient
by: P.V. Toledo, et al. -
Etymologia: Varicella Zoster Virus
Published: (2015-04-01) -
The Seroepidemiology of Varicella Zoster Virus (VZV) in Different Age Groups in Tehran, Iran
by: Zohreh Sharifi Sekyneh Emadi Ghanjin
Published: (2005-06-01)